

Attorney Docket No.: RTS-0147
Inventors: Bennett and Wyatt
Serial No.: 09/828,344
Filing Date: April 5, 2001
Page 2

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to nucleobases 26 through 61, nucleobases 117 through 220 of a 5'-untranslated region, nucleobases 268 through 351, nucleobases 440 through 572, nucleobases 652 through 1064, or nucleobases 1180 through 1207 of a coding region, or nucleobases 1239 through 1618, nucleobases 1707 through 1908, or nucleobases 2017 through 2062 of a 3'-untranslated region of a nucleic acid molecule encoding Phospholipid scramblase I (SEQ ID NO: 3), wherein said compound specifically hybridizes with one of said regions and inhibits the expression of Phospholipid scramblase I.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (previously canceled).

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Attorney Docket No.: **RTS-0147**
Inventors: **Bennett and Wyatt**
Serial No.: **09/828,344**
Filing Date: **April 5, 2001**
Page 3

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (previously canceled).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (previously amended): A method of inhibiting the expression of Phospholipid scramblase I in cells or tissues

Attorney Docket No.: **RTS-0147**
Inventors: **Bennett and Wyatt**
Serial No.: **09/828,344**
Filing Date: **April 5, 2001**
Page 4

comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of Phospholipid scramblase I is inhibited.

Claims 16-20 (previously canceled).